Area of research
Pulmonary and Respiratory Medicine · Cancer Research
Research interest
Research interests include Prostate Cancer Treatment and Research, Cancer, Lipids, and Metabolism, Radiopharmaceutical Chemistry and Applications, and Estrogen and related hormone effects.
Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress
Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer
PROX1 is an early driver of lineage plasticity in prostate cancer
Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas
Stromal-derived MAOB promotes prostate cancer growth and progression
Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer
Abstract 6574: UCHL1 is a molecular indicator and a therapeutic target for neuroendocrine carcinomas
Abstract 5968: CDC7 is a targetable regulator of advanced prostate cancer
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer
Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation
LSD1 Inhibition Disrupts Super-Enhancer–Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation
Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment
Co-evolution of <i>AR</i> gene copy number and structural complexity in endocrine therapy resistant prostate cancer
Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets
Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer
RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth
MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer
Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress
Prostate cancer reactivates developmental epigenomic programs during metastatic progression
Androgen receptor-induced integrin α6β1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer
Radium-223 mechanism of action: implications for use in treatment combinations